** Shares of Roivant Sciences ROIV.O fall 2.2% to $12.20 before the bell
** Co says its experimental lung disease drug, namilumab, did not meet the main and secondary goals in a mid-stage study
** Co was testing namilumab in patients with chronic active pulmonary sarcoidosis, a condition in which lumps of inflammatory cells form in the lungs
** Adds that it will stop further development of the drug to treat sarcoidosis
** As of last close, ROIV up 11% YTD
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。